Belkin Vision Bought for $81M by Alcon

Belkin Vision, a company that develops glaucoma devices, has been fully acquired by Alcon. With this arrangement, Alcon gains ownership of laser technology for addressing ocular hypertension and open angle glaucoma, with an initial payment of $81 million and potential milestone compensation totalling as much as $385 million.

Laser therapy is one of the recommended initial treatment options by the American Academy of Ophthalmology. However, there are hazards associated with the operation, including infection and clouded vision, and it needs skill to conduct, which may restrict popularity.

Belkin’s product, according to Alcon CEO David Endicott, is “a much simpler idea.” Because it doesn’t require the same amount of training or usage of a goniolens, the direct SLT solution is intended to simplify, expedite, and be safer.

Belkin has not yet begun selling the gadget in the United States, despite receiving 510(k) clearance from the FDA in December. The device is presently accessible in the European Union and the United Kingdom. The equipment will be incorporated into Alcon’s Alcon Vision Suite.